stockrow
Friday 6 November 2026
Export DFTX’s income statement to Excel — free account
Definium Therapeutics, Inc.
DFTX Healthcare Biotechnology
- EPS
- −188.0%
- Free cash flow
- −78.3%
- Total debt
- −11.5%
Quarter to June 2026, against a year earlier
33.27
2.91
+9.58%
Follow DFTX
Alert me
Definium Therapeutics, Inc. (DFTX) Net income
Definium Therapeutics, Inc.'s net income for fiscal 2025 was −$183.8M, compared with −$108.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$353.8M. Over the past ten years it has ranged from −$183.8M (fiscal 2025) to $0.00 (fiscal 2017) — the current reading is the lowest in ten years. Net income has fallen for 3 consecutive fiscal years. Definium Therapeutics, Inc. ranks 569th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$183.8M | — |
| FY2024 | −$108.7M | — |
| FY2023 | −$95.7M | — |
| FY2022 | −$56.8M | — |
| FY2021 | −$93.0M | — |
| FY2020 | −$33.9M | — |
| FY2019 | −$10.7M | — |
| FY2018 | −$630.8K | — |
| FY2017 | $0.00 | — |
| FY2016 | −$133.3K | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$159.0M | — |
| Mar 2026 | −$77.1M | — |
| Dec 2025 | −$50.4M | — |
| Sep 2025 | −$67.3M | — |
| 25 more quarters | Free account |
Against its own ten years
Low −$183.8M
High $0.00
Ten-year median
−$45.4M
Current reading's percentile
10
Net income against peers
| Company | Net income |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | $1.0B |
| ACAD ACADIA Pharmaceuticals Inc. compare | $362.2M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$56.2M |
| ABCL AbCellera Biologics Inc. compare | −$164.7M |
| DNTH Dianthus Therapeutics, Inc. compare | −$202.1M |
| ERAS Erasca, Inc. compare | −$287.2M |
| RLAY Relay Therapeutics, Inc. compare | −$293.6M |
| DFTX Definium Therapeutics, Inc. | −$353.8M |
| XENE Xenon Pharmaceuticals Inc. compare | −$409.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item